Centessa Pharmaceuticals plc (NASDAQ:CNTA) Shares Bought by Perceptive Advisors LLC

Perceptive Advisors LLC grew its stake in Centessa Pharmaceuticals plc (NASDAQ:CNTA) by 27.6% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,933,307 shares of the company’s stock after purchasing an additional 850,000 shares during the quarter. Perceptive Advisors LLC’s holdings in Centessa Pharmaceuticals were worth $35,518,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. First Light Asset Management LLC boosted its holdings in Centessa Pharmaceuticals by 59.2% in the 2nd quarter. First Light Asset Management LLC now owns 4,780,560 shares of the company’s stock worth $43,168,000 after buying an additional 1,778,515 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in shares of Centessa Pharmaceuticals by 16.5% in the first quarter. Price T Rowe Associates Inc. MD now owns 2,958,079 shares of the company’s stock worth $33,427,000 after acquiring an additional 418,615 shares during the last quarter. Driehaus Capital Management LLC increased its position in shares of Centessa Pharmaceuticals by 89.5% during the second quarter. Driehaus Capital Management LLC now owns 2,092,011 shares of the company’s stock worth $18,891,000 after purchasing an additional 987,997 shares in the last quarter. Octagon Capital Advisors LP raised its stake in Centessa Pharmaceuticals by 333.2% in the 4th quarter. Octagon Capital Advisors LP now owns 2,060,100 shares of the company’s stock valued at $16,398,000 after purchasing an additional 1,584,500 shares during the last quarter. Finally, Farallon Capital Management LLC raised its stake in Centessa Pharmaceuticals by 438.0% in the 2nd quarter. Farallon Capital Management LLC now owns 1,996,000 shares of the company’s stock valued at $18,024,000 after purchasing an additional 1,625,000 shares during the last quarter. Hedge funds and other institutional investors own 82.01% of the company’s stock.

Insider Activity at Centessa Pharmaceuticals

In other Centessa Pharmaceuticals news, CEO Saurabh Saha sold 4,169 shares of Centessa Pharmaceuticals stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $12.32, for a total transaction of $51,362.08. Following the completion of the sale, the chief executive officer now directly owns 827,755 shares in the company, valued at $10,197,941.60. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Centessa Pharmaceuticals news, insider Gregory M. Weinhoff sold 12,198 shares of the firm’s stock in a transaction that occurred on Thursday, August 22nd. The shares were sold at an average price of $12.17, for a total value of $148,449.66. Following the completion of the transaction, the insider now owns 241,171 shares of the company’s stock, valued at approximately $2,935,051.07. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Saurabh Saha sold 4,169 shares of the company’s stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $12.32, for a total value of $51,362.08. Following the sale, the chief executive officer now directly owns 827,755 shares in the company, valued at approximately $10,197,941.60. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 288,492 shares of company stock worth $4,641,902. Company insiders own 11.59% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the stock. BMO Capital Markets increased their target price on shares of Centessa Pharmaceuticals from $20.00 to $35.00 and gave the company an “outperform” rating in a research report on Monday, September 16th. Morgan Stanley upgraded shares of Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $11.00 to $26.00 in a report on Thursday, September 19th. B. Riley assumed coverage on shares of Centessa Pharmaceuticals in a research note on Thursday, September 19th. They issued a “buy” rating and a $33.00 target price on the stock. Oppenheimer restated an “outperform” rating and issued a $14.00 price target on shares of Centessa Pharmaceuticals in a research report on Wednesday, August 14th. Finally, Guggenheim lifted their price objective on Centessa Pharmaceuticals from $20.00 to $24.00 and gave the stock a “buy” rating in a research report on Wednesday, September 11th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $25.17.

Centessa Pharmaceuticals Stock Performance

Centessa Pharmaceuticals stock opened at $15.79 on Monday. The firm has a 50 day simple moving average of $13.01 and a 200-day simple moving average of $10.84. The stock has a market cap of $1.59 billion, a price-to-earnings ratio of -11.12 and a beta of 1.44. The company has a debt-to-equity ratio of 0.27, a current ratio of 13.29 and a quick ratio of 13.29. Centessa Pharmaceuticals plc has a 1-year low of $5.15 and a 1-year high of $17.59.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.02). On average, analysts expect that Centessa Pharmaceuticals plc will post -1.62 EPS for the current year.

Centessa Pharmaceuticals Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders.